40 results on '"Usmani, Saad Z"'
Search Results
2. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
3. Addressing the disparities: the approach to the African American patient with multiple myeloma
4. Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival
5. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
6. Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
7. Global disparities in patients with multiple myeloma: a rapid evidence assessment
8. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma
9. Extreme body mass index and survival in newly diagnosed multiple myeloma patients
10. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy
11. Extramedullary disease in multiple myeloma: a systematic literature review
12. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
13. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
14. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
15. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients
16. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis
17. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
18. Chromosome 1q21 abnormalities in multiple myeloma
19. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
20. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
21. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
22. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
23. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
24. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
25. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
26. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
27. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
28. Extramedullary Disease in Multiple Myeloma
29. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
30. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
31. Extramedullary multiple myeloma
32. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
33. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
34. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
35. Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma
36. Thalidomide and its analogues in the treatment of Multiple Myeloma
37. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
38. Duodenal MALT Lymphoma Presenting With Obstructive Jaundice: Report of a Case and Review of the Literature
39. Multifaceted Role of Rho Proteins in Angiogenesis
40. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.